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Introduction
Leptospirosis, a zoonosis with a worldwide distribution, is an acute 
febrile illness caused by microorganisms of the genus Leptospira [1]. 
Leptospires enter the body through small cuts or abrasions, via mucous 
membranes such as the conjunctiva and possibly through wet skin and 
circulate in the blood stream, with a bacteremic phase lasting for up to 
10 days post onset of the disease (DPO). The disease has a sudden onset 
with headache, fever, malaise, myalgia, conjunctival suffusion and 
sometimes a transient rash. Thereafter, the illness may rapidly develop 
into a severe, potentially fatal form with a high mortality rate. Because of 
the wide diversity of clinical signs, diagnosis of leptospirosis is difficult 
and depends upon a variety of laboratory assays such as detection of 
specific antibodies in the blood by microscopic agglutination test (MAT) 
and enzyme-linked immunosorbent assays (ELISA). Leptospires or 
their components may be detected in blood, urine or tissues by culture, 
dark field microscopy, immuno-staining or PCR [2,3]. The diagnosis of 
leptospirosis is not usually done on bacterial detection, but is mainly 
based on serology. Culturing provides proof of infection but is tedious 
and slow. This results in a high percentage of false negative findings, 
whereas the sensitivity of culturing usually does not exceed 20% [4–
6]. The MAT is the reference standard in serodiagnosis. It is the most 
widely used diagnostic test for leptospirosis in the world and presents 
the only serological test that can be applied on any infected mammalian 
species. The MAT has the advantage of being specific for serogroups, 
although cross reactions and paradoxical reactions between serogroups 
do occur [7]. However, there are limitations in sensitivity in the early 
phase of the disease since detectable titers of antibodies appear in the 
blood about 5–10 days after the onset of disease [3], and sometimes 
later, especially if antibiotic treatment is instituted [8]. In addition, 
cross-agglutination of antibodies against other diseases and repeated 
exposure to Leptospira in endemic regions cause background titers 
[8,9]. The performance of the MAT is further complicated because 
live cultures of different Leptospira serovars prevalent in a particular 
geographical area are required for optimal performance [8]. Thus, the 
leptospirosis case definition including laboratory parameters varies 
in different epidemiological backgrounds and ideally requires local 
assessments of the laboratory tests. However, valid determination of 
cut-off titers for case definition is only scarcely done [9] or are not 
publicly presented [10,11] and current case definitions are mainly 
based on general assumptions and experience of experts [8,12,13]. In 
addition, case definitions formulate clinical manifestations either too 
wide or specify only forms of severe disease with signs and symptoms 
that often develop in the immune phase of the disease, when antibiotic 
treatment is less effective [14,15]. The lack of well defined laboratory 
criteria for regional case definitions is mainly due to a lacking knowledge 
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Abstract
Laboratory case definition of leptospirosis is scarcely defined by a solid evaluation that determines cut-off values 
in the tests that are applied. This study describes the process of determining optimal cut-off titers of laboratory tests 
for leptospirosis for a valid case definition of leptospirosis. In this case the tests are the microscopic agglutination test 
(MAT) and an in-house IgM enzyme-linked immunosorbent assay (ELISA) both on single serum and paired samples 
using a positive culture as the reference test in the Dutch population. The specificity was assessed using panels of 
sera from healthy donors, cases with known other diseases and non-leptospirosis cases with symptoms compatible 
with leptospirosis. Cases were divided into three periods corroborating the acute phase (1-10 days post onset of illness 
(DPO)), the early convalescent (11-20 DPO) and the late convalescent phase (>20 DPO). Cut-off titers for MAT and 
IgM ELISA were determined as 1:160 and 1:80 respectively for all three periods. These cut-off titers combined 100% 
specificity with a sensitivity that changed according to the stage of disease for both tests. The low sensitivities in the 
early acute phase are consistent with the dynamics of the humoral immune response. IgM ELISA yielded higher 
sensitivities compared to MAT in the acute and early convalescent stages. Moreover, the optimal sensitivity of MAT, the 
gold standard was < 82%, implying that a significant part of global cases is missed by this recommended test. MAT and 
IgM ELISA manifested partly complementary, resulting in a higher sensitivity when combining the results of these two 
tests. The availability of paired samples and of adequate clinical and epidemiological data are other parameters that will 
significantly increase the sensitivity of laboratory confirmation. This study enables fine-tuning of the current laboratory 
definition towards an improved case finding and implies that solid validation of laboratory parameters for case definition 
will improve both the diagnosis for individual patient care and for estimating the disease burden at a worldwide scale.
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on the assessment of optimal diagnostic accuracies of tests as well as on 
the easy availability of globally recommended criteria [8,12]. The global 
criterion for laboratory confirmation of a current Leptospira infection 
is usually defined as seroconversion or a four-fold rise in titer in paired 
serum samples or set at a single MAT titer ≥ 1:400 in the presence 
of clinical signs and appropriate history of animal contact [16]. This 
research describes the process of establishing optimal cut-off titers of 
tests for leptospirosis in order to obtain a valid laboratory case definition 
of leptospirosis, in this case the performance of MAT and ELISA in the 
population of The Netherlands. For this purpose, a positive culture is 
used as the reference test to define a case. For the clinical setting it is 
important to know how to interpret these diagnostic tests in relation to 
the time of sampling. Although cut-off titers will vary across distinct 
endemic situations, still this assessment will serve as a valuable example 
for others, irrespective the local situation. An improved, tailor-made 
case definition enables a better case finding and thus will contribute to 
an improved worldwide diagnosis of leptospirosis.
Materials and Methods
Patients and sera
Culture positive patients: In the period of investigation, the 
population in The Netherlands increased from 14.1 to 16.4 million 
with a median of 15.6 million. The WHO/FAO/OIE and National 
Collaborating Centre for Reference and Research on Leptospirosis 
(NRL) at KIT Biomedical Research in Amsterdam receives clinical 
material (whole blood, serum, EDTA blood, heparinized blood or 
urine) for testing from every patient suspected for leptospirosis 
in the Netherlands. Yearly, NRL receives about 600 specimens of 
suspected patients and confirms on average 30 cases [5,6]. Nowadays 
approximately 50% of the confirmed cases are imported infections, 
usually associated to adventurous activities such as white water rafting 
or jungle tracking during vacation in tropical countries [4,17]. Culture 
on blood is performed when sampled within 10 days after onset of 
symptoms. Culture on urine can be perfomed at any timepoint in the 
disease, allthough not often requested since the inoculation into the 
culture medium has to take place within two hours after voiding. From 
each blood sample routine diagnostics are performed by MAT and 
IgM ELISA. In the period 1980-2009 leptospirosis was confirmed by 
a positive culture in 107 patients, referred to as ‘cases’ in this paper. 
Samples were selected from these cases in order to have no more than 
one sample of each patient in each of the time periods 1 to 10 DPO, 
11 to 20 DPO and more than 20 DPO according to the most relevant 
periods for laboratory confirmation. The first period is the acute phase 
defined by low sensitivity because of the absence of detectable amounts 
of antibodies in most samples. Antibody levels reach a maximum after 
about 10 days [18] and are well detectable in the early convalescent 
phase and steadily decrease after 20 days [3]. When multiple samples of 
one patient were present in a period of time, the sample with the lowest 
DPO was chosen (Table 1). 
Healthy controls: Sera (n=110) from healthy blood bank donors 
were obtained from the local blood bank and served as healthy controls 
to determine cross-reacting antibodies in the population.
Controls with known disease to determine specificity based on 
selectivity: The following controls with known disease were used to 
screen for cross-reactivity to determine specificity based on selectivity. 
Sera from patients with human immunodeficiency virus (HIV) infection 
(n=20), hepatitis A virus infection (n=10), hepatitis B virus infection 
(n=9), malaria (n=20), toxoplasmosis (n=11) and meningococcal 
meningitis (n=20) since these infectious agents could cause symptoms 
similar to leptospirosis. Moreover, a control group with proven syphilis 
(n=19), also a spirochete and related to Leptospira  and a group with 
autoimmune disease (rheumatoid arthritis, n=10; systemic lupus 
erythematosus, n=20) were used since these diseases are notorious for 
generating cross-reactive antibodies. These samples are referred to as 
‘known controls’.
Controls with unknown disease: Sera were taken from patients 
suspected of leptospirosis but having a negative culture and for whom 
leptospirosis could not be confirmed. These samples are referred to 
as ‘unknown controls’ and were divided into an acute set, 1-10 DPO 
(n=62) and a convalescent set, >10 DPO (n=63).
Laboratory tests
Microscopic agglutination test: The microscopic agglutination 
test (MAT) was performed with a panel of live leptospires as described 
previously [19]. The panel consisted of 16 strains of the pathogenic 
serovars Bratislava, Ballum, Canicola, Grippotyphosa, Hebdomadis, 
Icterohaemorrhagiae, Copenhageni, Poi, Pomona, Proechimys, Hardjo, 
Saxkoebing and Sejroe, and the non-pathogenic serovar Patoc. The sera 
from patients who were probably infected abroad were additionally 
examined by using a second panel of 12 strains representative of 
global leptospires, comprising the pathogenic serovars Australis, 
Rachmati, Bataviae, Celledoni, Cynopteri, Mini, Panama, Pyrogenes, 
Shermani and Tarassovi, and the non-pathogenic serovars Andamana 
and Semaranga. Non-pathogenic serovars were included to detect 
cross-agglutinating antibodies against pathogenic serovars that are 
not represented in the panels. Titers with these saprophytic serovars 
have no diagnostic relevance and are excluded from this assessment. 
Agglutination was performed in microtiter plates with serial twofold 
dilutions of the sera starting at 1:20 (5µl of serum, 45µl of phosphate 
buffered saline, and 50µl of antigen, incubated for 2-4 hours at 30°C). 
Agglutination was examined by dark-field microscopy. The titer was 
defined as the highest dilution giving 50% agglutination in comparison 
with that of the negative control [8,20]. 
IgM ELISA: The in-house developed ELISA for the detection of 
Leptospira-specific IgM antibodies (IgM ELISA) was performed with 
antigen prepared from a well grown culture of the local strain Wijnberg 
(serovar Copenhageni, serogroup Icterohaemorrhagiae) in EMJH 
medium [21]. The culture was killed by formalin (final concentration 
0.5% v/v), heated in a boiling water bath for 30 min and centrifuged for 
30 min at 10,000g. The supernatant was used for antigen. In each well 
of polystyrene micro titer plates (Greiner, Frickenhausen, Germany, 
Microlon 96 wells plates, medium binding) 100µl of the supernatant 
was left to evaporate at room temperature. The coated plates were 
Patients (n) Samples (n) per patient Sample taken from patients (n) at time period
DPO 1-10* DPO 11-20 DPO >20
15 1 11** 0 4
58 2 26 26
29 29
3 3
30 3 30 30 30
*Where 1-10 DPO is divided into 1-4 and 5-10 DPO the number of samples is 48 
respectively 62.
** 5 of these patients have died therefore no follow up sample is available
Table 1: Samples selected according to disease period expressed as days post 
onset (DPO).
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stored in a dry place at room temperature [20]. Before use, the plates 
were thoroughly washed with phosphate buffered saline (PBS) pH 7.2, 
containing 0.05% Tween 20 and serial twofold dilutions were made of 
the sera starting at 1:10 (10µl serum and 90µl of PBS containing 0.05% 
Tween 20 and 0.5% bovine serum albumin). After incubation with the 
serum dilutions for 1 h at 30°C the micro titer plates were washed and 
subsequently incubated with peroxidase-conjugated anti-human IgM 
(Biorad, Veenendaal, the Netherlands). After 1h incubation at 30°C, 
the plates were washed again and finally incubated with substrate 
(5-aminosalicylic acid; Merck). After 2 h the reaction was read at 
wavelength 492 nm. The titer was the last dilution giving an absorbance 
of more than half the value of a positive control serum [20]. 
Culture: The culture medium used was of Ellinghausen-
McCullough as modified by Johnson and Harris (EMJH) supplemented 
with 5-fluorouracil (200µg/ml) (EMJH-FU) [8,16] rabbit serum (EMJH-
RS) and 1% (V/V) fetal calf serum (EMJH-FCS) or combinations. 
Fletcher medium was prepared according to standard protocols [8,20]. 
The culture was done on blood (approximately 150µl) which was 
inoculated into the following culture media (6 ml): Fletcher medium, 
EMJH, EMJH-FU, EMJH-FCS-RS, and EMJH-FCS-RS-FU. Urine was 
diluted 1:10, 1:100 and 1:100 onto EMJH-FU and EMJH-FCS-RS-FU. 
Inoculated media are incubated for a maximum of 4 months at 30°C 
and biweekly checked for leptospiral growth by darkfield microscopy. 
Data collection
From each sample Patient ID, sample ID, highest titer in MAT 
with the pathogenic strains, IgM ELISA titer and days post onset of 
symptoms (DPO) were retrieved from the KIT archives and entered 
into EPI INFO version 6.
Analyses
Sensitivity and corresponding confidence intervals was calculated 
for each cut-off titer by dividing the number of cases having at 
least this titer by the total number of cases. This was done for three 
time periods (1-10 DPO, 11-20 DPO and >20 DPO). Specificity 
and corresponding confidence intervals was calculated for three 
subgroups: healthy controls, known controls and unknown controls. 
The unknown controls were divided into two time points, 1-10 DPO 
and >10 DPO. Receiver Operating Characteristic (ROC) curves were 
constructed in Microsoft Excel. These curves show the true positive 
rate (in the cases) against the false positive rate (for each of the control 
subgroups) for the different cut-off titers of the MAT and IgM ELISA. 
For both tests for each time period (1-10 DPO, 11-20 DPO and >20 
DPO) the cut-off values yielding an optimal combination of sensitivity 
and specificity were chosen. During the acute phase, detectable levels 
of anti-Leptospira antibodies are produced, so it can be expected that 
the sensitivity of MAT and IgM ELISA is much lower in the early 
acute phase (DPO <5). Therefore the acute phase was divided into 1 
to 4 days and 5 to 10 days. From the optimal values combinations of 
MAT AND/OR IgM ELISA were made, and sensitivity and specificity 
were calculated on the complete dataset. ROC curves were plotted from 
these combinations in order to find out whether the sensitivity and/or 
specificity can be increased by combining the results from both tests. 
In the diagnosis of leptospirosis the optimal cut-off values are defined 
as those titers having the highest specificity. Confidence intervals will 
aid in determining which sensitivity and specificity are most precise 
based on the data. Results are presented based on MAT and IgM ELISA 
values on single sera, combinations of MAT AND/OR IgM ELISA 
values on single sera and seroconversion in paired sera. Serology on 
paired sera is much more reliable compared to a single sample [13] 
since a follow-up sample will take into account the effect of background 
or cross-reacting titers. Thus an optimal specificity is reached at a lower 
titer. We therefore argued that a one-step lower cut-off titer can be used 
for MAT and IgM ELISA on paired samples, herewith increasing the 
test sensitivity. Hence, the sensitivity is calculated on follow up samples 
using one-step lower cut-off titers in the tests. Paired samples from 68 
cases were used to check the integrity of this approach. 
Results
Patient samples
The total number of positive leptospirosis cases in the period 1980-
2009 (based on culture and/or serology) is 919. One hundred and seven 
cases were found culture positive (11.6%). Leptospires were isolated 
from urine in 8 cases and from blood in 99 cases. Four cases were 
excluded from the analysis: first day of illness was not documented in 
three cases and ELISA results were missing in one case. The remaining 
group of 103 cases consisted of 95 men of whom 6 died (ranging from 
6 to 30 DPO, median 7 DPO), and 8 women. Serovars belonging to 
the following serogroups were isolated: Icterohaemorrhagiae n=57, 
Grippotyphosa n=17, Autumnalis n=6, Celledoni n=3, Hebdomadis 
n=3, Pyrogenes n=3, Sejroe n=3, Bataviae n=2, Canicola n=2, Javanica 
n=2, Pomona n=2, Shermani n=2, Cynopteri n=1. 
Determination of cut-off titers on single sera for MAT and 
IgM ELISA
The ROC curves showing the relationship between sensitivity and 
specificity according to each the acute phase and the early and late 
convalescent phases are depicted in Figure 1. The ROC curves include 
the most optimal sensitivity-specificity distribution for the set of 
healthy blood donors and indicate, as expected, that the specificity of 
MAT and IgM ELISA is not limited by cross-reacting antibodies in the 
healthy population. ROC curves for the known and unknown controls 
largely coincided, albeit that the IgM ELISA seemed to perform more 
stable than MAT. Specificity based on known controls (selectivity) 
indicates that cross-reacting antibodies to other diseases may interfere 
with the diagnosis and as such have importance that cannot be ignored. 
However, this selectivity is biased by inclusion of diseases that are 
unlikely to be confused with leptospirosis and overrates their impact 
on the practical situation that is better presented by the specificity 
based on unknown controls. Therefore, specificity based on unknown 
controls was selected as the most important parameter for further 
assessment of optimal cut-off values. From the ROC plots, MAT and 
IgM ELISA titers were selected for which optimal sensitivity and 
specificity was achieved for each time period (Table 2). When several 
optimal values were close together on the ROC curve all those values 
were listed in the table, the combination with the highest specificity 
being marked. For IgM ELISA a cut-off titer of ≥1:80 signified 100% 
specificity in all periods and was selected as the optimal cut-off value. 
This was associated with sensitivities of 25.0%, 91.7% and 70.8% for the 
time periods 1- 10 DPO, 11-20 DPO and >20 DPO, respectively. Cut-
off titers of ≥1:40 did give a higher sensitivity in all categories but were 
associated with a lower specificity (Table 2). For MAT, 100% specificity 
was reached at a cut-off titer of ≥1:160. This was associated with a lower 
selectivity of 96.4% (not shown) and corresponded to sensitivities of 
6.3%, 81.7% and 81.5%, for periods 1-10 DPO, 11-20 DPO and >20 
DPO, respectively. 
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Figure 1:  Receiver Operating Characteristic (ROC) Curve of cut-off titers of MAT and ELISA in different time periods healthy controls “_”, known controls“ ”, unknown 
controls“ ”.
To investigate the acute phase, the time period 1-10 DPO was 
divided into two periods of 1-4 DPO (early acute) and 5-10 DPO 
(late acute). As expected, at the cut-off titer of ≥1:80, the sensitivity 
of IgM ELISA was only 6.3% in the early acute phase but rapidly 
increased to 53.2% in the late acute phase. For MAT this was 2.1 and 
24.2%, respectively (Figure 2). This supports the notion that serology 
has minor importance at the very early phase of disease and only 
becomes useful during the second half of the first week of illness. The 
sensitivities of MAT in the acute phase are markedly lower than those 
of IgM ELISA, showing that IgM ELISA tends to give an earlier positive 
outcome compared to MAT. 
Determination of cut-off titers on single sera for MAT 
combined with IgM ELISA: From the results in Table 2, sensitivities 
and specificities were calculated for all possible combinations of 
MAT and IgM ELISA in the samples and plotted in ROC curves (not 
shown). The optimal values of these combinations are shown in Table 
3. Considering the limitations inflicted on MAT by the selectivity, 
the optimal cut-off titer of the MAT was again set to ≥1:160. For the 
categories DPO 1-10, both the cut-off titer combinations ‘MAT ≥1:160 
OR IgM ELISA ≥1:80’ and ‘MAT ≥1:160 AND IgM ELISA ≥1:80’ did 
give 100% specificity but the sensitivity was much higher (25%) in the 
combination ‘OR’. As indicated by the results for the separate tests, 
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DPO Cut-off titer
MAT
Sensitivity 
(%)
95% CI
MAT
Specificity*  
(%)
95% CI
IgM ELISA
Sensitivity
(%)
95% CI IgM ELISA Specificity* (%) 95% CI
1-10
≥1:40 19.8 13.1-28.9 79.0 67.4-87.3 31.3 22.9-41.1 96.8 89.0-99.1
≥1:80 12.5 7.3-20.6 93.5 84.6-97.5 25.0 17.4-34.5 100.0 94.2-100
≥1:160 6.3 2.9-13.0 100.0 94.2-100.0 16.7 10.5-25.4 100.0 94.2-100
11-20
≥1:40 95.0 86.3-98.3 71.4 59.3-81.1 96.7 88.6-99.1 93.7 84.8-97.5
≥1:80 90.0 79.9-95.3 90.5 80.7-95.6 91.7 81.9-96.4 100.0 94.2-100.0
≥1:160 81.7 70.1-89.4 100.0 94.2-100.0 85.0 73.9-91.9 100.0 94.2-100.0
>20
≥1:40 92.3 83.2-96.7 71.4 59.3-81.1 89.2 79.4-94.7 93.7 84.8-97.5
≥1:80 87.7 77.5-93.6 90.5 80.7-95.6 70.8 58.8-80.4 100.0 94.2-100.0
≥1:160 81.5 70.4-89.1 100.0 94.2-100.0 58.5 46.3-69.6 100.0 94.2-100.0
Bold text indicates the optimal cut-off for sensitivity and specificity based on the ROC plots with priority on a high specificity *specificity based on unknown controls
Table 2: Sensitivity and specificity and corresponding 95% confidence intervals (CI) of either MAT or IgM ELISA.
serology on early acute sera samples is not very helpful, also when 
combining the titers of the two tests (Figure 2). However, for DPO 
5-10, the cut- off titer combination ‘MAT ≥1:160 OR IgM ELISA ≥1:80’ 
represented a sensitivity of 53.2% with a specificity of 100% (Figure 2). 
In the period 1-10 DPO, all samples having a MAT titer ≥1:160 also 
had an IgM ELISA titer of ≥1:80, so the sensitivity of ‘MAT ≥1:160 
OR IgM ELISA ≥1:80’ is determined by the IgM ELISA. The optimal 
combination for both the periods 11-20 DPO and >20 DPO was ‘MAT 
≥1:160 OR IgM ELISA ≥1:80’. Specificity was in both periods 100% and 
associated with a decrease of sensitivity from 93.3 to 89.2% in the later 
stage, reflecting the decrease of antibody levels in the late convalescent 
stage of disease [3]. 
Paired samples
Sensitivity for follow up samples or samples that are accompanied 
by clinical and epidemiological data compatible with leptospirosis was 
calculated for a cut-off titer 1:40 for IgM ELISA and 1:80 for the MAT, 
accounting both for seroconversion and a minimal 4-fold titer rise in 
both tests. For the time period 1-10 DPO, this implied a sensitivity 
of 12.5 and 31.3% for MAT and IgM ELISA, respectively (Table 2). 
For the category 11-20 DPO this was 90.0% and 96.7% respectively, 
declining to 87.7%, and 89.2% for >20 DPO. When combining the 
MAT and IgM ELISA results at these cut-off titers, the three categories 
had sensitivities of 33.3, 96.7 and 95.4%, respectively (Table 3). In our 
study, 68 paired samples with initial titers not fulfilling the cut-off titer 
combination ‘MAT ≥1:160 OR IgM ELISA ≥1:80’, showed in 67 cases 
(98.5%) in the follow up sample seroconversion or at least a four-fold 
titer rise after 2 to 121 days (median 12 days). Sixty three cases did 
show seroconversion or titer rise in the follow up sample exceeding 
DPO Cut-off titer MAT AND/OR
Cut-off 
titer 
IgM ELISA
Sensitivity (%) 95% CI Specificity (%) 95% CI
1-10
≥1:80 AND ≥1:40 10.4 5.8-18.1 100.0 94.2-100.0
≥1:80 OR ≥1:40 33.3 24.7-43.2 90.3 80.4-95.5
≥1:80 AND ≥1:80 10.4 5.8-18.1 100.0 94.2-100.0
≥1:80 OR ≥1:80 27.1 19.2-36.7 93.5 84.6-97.5
≥1:160 AND ≥1:40 6.3 2.9-13.0 100.0 94.2-100.0
≥1:160 OR ≥1:40 31.3 22.9-41.1 96.8 89.0-99.1
≥1:160 AND ≥1:80 6.3 2.9-13.0 100.0 94.2-100.0
≥1:160 OR ≥1:80 25.0 17.4-34.5 100.0 94.2-100.0
11-20
≥1:80 AND ≥1:40 90.0 79.9-95.3 98.4 91.5-99.7
≥1:80 OR ≥1:40 96.7 88.6-99.1 85.7 75.0-92.3
≥1:80 AND ≥1:80 86.7 75.8-93.1 100.0 94.2-100.0
≥1:80 OR ≥1:80 95.0 86.3-98.3 90.5 80.7-95.6
≥1:160 AND ≥1:40 81.7 70.1-89.4 100.0 94.2-100.0
≥1:160 OR ≥1:40 96.7 88.6-99.1 93.7 84.8-97.5
≥1:160 AND ≥1:80 80.0 68.2-88.2 100.0 94.2-100.0
≥1:160 OR ≥1:80 93.3 84.1-97.4 100.0 94.2-100.0
>20
≥1:80 AND ≥1:40 81.5 70.4-89.1 98.4 91.5-99.7
≥1:80 OR ≥1:40 95.4 87.3-98.4 85.7 75.0-92.3
≥1:80 AND ≥1:80 67.7 55.6-77.8 100.0 94.2-100.0
≥1:80 OR ≥1:80 90.8 81.3-95.7 90.5 80.7-95.6
≥1:160 AND ≥1:40 76.9 65.4-85.5 100.0 94.2-100.0
≥1:160 OR ≥1:40 93.8 85.2-97.6 93.7 84.8-97.5
≥1:160 AND ≥1:80 63.1 50.9-73.8 100.0 94.2-100.0
≥1:160 OR ≥1:80 89.2 79.4-94.7 100.0 94.2-100.0
Bold text indicates the optimal cut-off for sensitivity and specificity combinations with priority on a high specificity.
Table 3: Optimal sensitivity and specificity by combining MAT and IgM ELISA results.
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the criteria set for a single sample, while another four did meet the 
criteria set for paired samples. The case not showing seroconversion 
was infected with serovar Grippotyphosa; samples were taken on 3 and 
30 DPO.
Discussion
Together with the difficult diagnosis of leptospirosis both in the 
clinic and in the laboratory, inadequate case definitions probably form 
a major cause for the global underestimation and unawareness of the 
disease. Good knowledge on how to assess optimal accuracy of 
laboratory tests is mostly lacking and general recommended criteria, 
rather than tailor-made ones, are adopted. In this retrospective case 
control study, the optimal cut-off values for leptospirosis confirmation 
by MAT and IgM ELISA in The Netherlands are determined, using 
positive culturing results as the reference test. Taking into account the 
dynamics of the humoral response [3], single samples were analysed 
according to three time periods, i.e. the acute stage of illness (1-10 
DPO), the early convalescent stage (11-20 DPO) and the late 
convalescent stage (>20 DPO). Cut-off titers of 1:80 and 1:160 for IgM 
ELISA and MAT were determined for all three periods. This was 
associated with a specificity of 100% for both tests. However, the 
sensitivities varied markedly from 6.3 to 81.7% for MAT and 25.0 to 
91.7% for IgM ELISA in the acute and early convalescent phase. Thus, 
sensitivities of MAT and IgM ELISA are low at the acute stage of illness 
and require a follow-up sample for confirming seroconversion or a 
significant titer rise. To assess the impact of the increasing immune 
response on the diagnostic outcome in more detail, the acute phase was 
split in an early (1-4 DPO) and late (5-10 DPO) stage. Rapid increases 
in sensitivity in both tests across the two stages were noticed; i.e. the 
sensitivity for MAT rose from 2.1 to 24.2% and the sensitivity of the 
IgM ELISA from 6.3% to 53.2%. Moreover, testing paired samples 
markedly increased the sensitivity of the diagnosis. This justifies two 
conclusions. (i) These findings support the notion that serology has 
minor importance at the very early phase of disease. (ii) These results 
underline the importance of using a follow up sample for confirmation 
by serology. However, unlike generally stated that paired samples 
should preferably be collected two weeks apart [13], much shorter 
intervals appear relevant. Seroconversion was observed in samples 
taken as few as two days apart. Therefore, we advocate the use of 
repeated samples, albeit at intervals of one week or shorter in case of 
urgent suspicion. The MAT is the reference test in serodiagnosis of 
leptospirosis and is often referred to as the gold standard. This 
nomination is not supported by this study. MAT was at the best 81.7% 
sensitive in the convalescent stage, implying that 2 of 10 cases are 
missed when only MAT is used on a single sample. The IgM ELISA did 
perform much better (sensitivity 91.7%) and was significantly more 
sensitive compared to MAT in the late acute stage of illness. It is 
therefore tempting to designate IgM ELISA as the new gold standard. 
There are, however, caveats. This study was performed on Dutch cases 
with low infection backgrounds and concerned an in-house ELISA. 
This ELISA is based on the determination of a titer from serial dilutions 
[19,22]. This approach is probably more robust than using single well 
platforms and, hence, our results cannot be translated to these other 
formats. Moreover, high prevalence countries might have higher 
background titers, requiring different cut-off titers of both MAT and 
ELISA that might favour the use of MAT. Additionally, unlike MAT, 
ELISA is a genus specific tests that does not enable the assessment of 
presumptive infecting serogroups, and as such lacks an important 
epidemiological application. In The Netherlands, MAT is always 
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performed along with IgM ELISA. Therefore the impact of diagnostic 
value by combining the results of both tests was investigated. 
Combination of tests had no effect on the acute phase of the disease 
that was dominated by the sensitivity of the IgM ELISA but resulted in 
a markedly increased sensitivity in the early convalescent stage. 
Applying cut-off titers of 1:160 and 1:80 for MAT and IgM ELISA, a 
sensitivity of 93.3% was reached by combining MAT ‘OR’ IgM ELISA 
results, comparing to 81.7 and 91.7%, for each test, respectively. 
Apparently, the two tests are partly complementary at this stage of 
illness. This observation substantiates the importance of using two 
distinct tests. This study unambiguously demonstrates that serology 
largely fails in the acute phase of the disease. This period is of most 
clinical importance because adequate antibiotic treatment has to be 
initiated as early in the illness as possible [14,15]. Thus, serology is not 
very helpful in an early stage of leptospirosis when confirmation is 
most required. Late confirmation by serological testing, presents a 
major obstacle in clinical decision making. Clinicians have to rely on 
their own judgement based on mostly uncharacteristic symptoms to 
initiate appropriate (antibiotic) treatment. On one hand, low titers 
during early illness are highly unreliable because of a low accompanying 
specificity (Table 2). On the other hand, such low titers might be a sign 
of a developing leptospirosis and as such, should not be ignored. We 
deal with this contradiction by informing the consulting clinician 
promptly upon finding low reactions and explain their significance. 
Following this strategy, the clinician is provided with early indications 
on a potential Leptospira infection that support decisions on the 
initiation or pursuit of a suitable treatment. Fortunately, nowadays 
validated real time PCRs are available [23,24]. These PCRs have a high 
diagnostic accuracy notably in this early acute phase, hence perfectly 
complementing serodiagnostic testing. We are aware that a lack of 
experience and financial potential might hamper the introduction of 
real time PCR notably in those regions where the disease is highly 
prevalent but, nevertheless, strongly recommend its implementation in 
the diagnostic services. In absence of real time PCR, laboratory testing 
will largely benefit from well established criteria that define positive 
outcomes of serological testing. The study described in this paper 
serves as a template for other such studies in distinct epidemiogical 
settings. Such local evaluation is of great importance because different 
cut-off titers in the MAT have been demonstrated in high compared to 
low endemic situations [9]. In our study, relatively low cut-off titers for 
MAT were defined, i.e., ≥1:160 for single samples and ≥1:80 for paired 
samples. There are two reasons for these low cut-off titers: (i) The 
infection background in The Netherlands is low and as such impacts to 
a lesser extent on the specificity. This also counts for the IgM ELISA. 
(ii) Historically, at NRL Leptospira strains are not diluted before 
performing the MAT as recommended [8] but full grown cultures are 
used. A higher density of Leptospira strains will reduce the titer by one 
dilution step at the minimum [16]. Consistently, in the MAT proficiency 
testing, we find our titers below the median titer [25]. Cut-off titers are 
based on single serum samples, without information on adequate 
clinical and epidemiological findings. It is common notice that 
knowledge of clinical and epidemiological data are highly valuable and 
should largely contribute to the confirmation of suspected leptospirosis 
[8,26]. For the same, testing of paired serum samples is strongly 
recommended and case definitions use lower cut-off titers on paired 
samples than on single ones [8,12]. In line with this argument, we 
applied cut-off titers that were one dilution step lower than those 
deduced for single samples. When testing this approach on a set of 68 
paired samples, all but one fulfilled the criteria of these lower cut-off 
titers. The one exception was an infection with Grippotyphosa that did 
not give any detectable antibody response. Grippotyphosa infections 
are notorious for causing transient or delayed immune responses that 
might be missed [3,8,11]. Our evaluation allowed us to change our 
current and more stringent case definition based on preliminary data 
analysis on single serum samples [27] and consequently is expected to 
improve the case finding in The Netherlands. The use of different cut-
off values in different epidemiological situations might lead to 
confusion. Therefore, we have designed an algorithm, assisting with 
interpretations and conclusions on the outcome of our laboratory 
testing (Figure 3). This algorithm includes application of a validated 
real time PCR [23]. We anticipate that the assessment of our case 
definition as well as the algorithm presented in this paper is not only 
useful for application in The Netherlands but can easily be adapted into 
a useful assessment tool in different epidemiological backgrounds. As a 
concluding remark we mention that a lack of notification is not the 
only reason for the underestimation of leptospirosis [28]. As we have 
shown, inadequate case definition and a questionable sensitivity of the 
reference MAT both are also causes of missing cases.
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